Brivanib alaninate
Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Brivanib alaninate is a multitargeted tyrosine kinase inhibitor (as is sorafenib).
Wikipage redirect
primaryTopic
Brivanib alaninate
Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Brivanib alaninate is a multitargeted tyrosine kinase inhibitor (as is sorafenib).
has abstract
Brivanib alaninate (INN/USAN) ...... 000 patients around the world.
@en
ATC prefix
CAS number
649735-63-7
IUPAC name
(S)-(R)-1-((4-((4-fluoro-2-met ...... )propan-2-yl 2-aminopropanoate
@en
PubChem
thumbnail
Link from a Wikipage to an external page
Wikipage page ID
34,793,637
Wikipage revision ID
728,664,772
ChEMBL
ChemSpiderID
IUPHAR ligand
legal status
Investigational new drug
molecular weight
routes of administration
smiles
CC1=CC2=CC=CCOC3=NC=NN4C3=CC
StdInChIKey
LTEJRLHKIYCEOX-OCCSQVGLSA-N
hypernym
comment
Brivanib alaninate (INN/USAN) ...... e inhibitor (as is sorafenib).
@en
label
Brivanib alaninate
@en
